Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model | Zendy

César A. Arias | Zendy; Kavindra V. Singh | Zendy; Diana Panesso | Zendy; Barbara E. Murray | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model

Author(s) -

César A. Arias,

Kavindra V. Singh,

Diana Panesso,

Barbara E. Murray

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkm237

Subject(s) - enterococcus faecalis , microbiology and biotechnology , ampicillin , vancomycin , antibacterial agent , cephalosporin , staphylococcus aureus , pharmacology , antibiotics , chemistry , medicine , biology , bacteria , genetics

Ceftobiprole is a novel broad-spectrum cephalosporin with good in vitro activity against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. The objective of this study was to assess the in vivo activity of ceftobiprole against four strains of E. faecalis, including beta-lactamase- producing (Bla+) and vancomycin-resistant strains.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research